Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2014 - 2026)

Viking Therapeutics has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $521.9 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 36.96% year-over-year to $521.9 million; the TTM figure through Jun 2026 stood at $2.6 billion (down 26.99% YoY), while the FY2025 annual figure was $715.7 million, down 21.2% from the prior year.
• Liabilities and Shareholders Equity came in at $521.9 million for Q2 2026 at Viking Therapeutics, down from $608.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $967.5 million in Q1 2024 to a low of $150.9 million in Q1 2023.
• Average Liabilities and Shareholders Equity over 5 years is $558.6 million, with a median of $565.1 million recorded in 2026.
• Year-over-year, Liabilities and Shareholders Equity jumped 541.19% in 2024 and tumbled 36.96% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $168.5 million in 2022, then jumped by 118.65% to $368.5 million in 2023, then soared by 146.5% to $908.3 million in 2024, then dropped by 21.2% to $715.7 million in 2025, then slipped by 27.08% to $521.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $521.9 million in Q2 2026, $608.2 million in Q1 2026, and $715.7 million in Q4 2025.